How 'lung-on-a-chip' models are advancing COVID drugs To view this email as a web page,
click here | | Webinar: Signaling Pathway CDx for Therapy Response Prediction Wednesday, May 26, 2021 | 11am ET / 8am PT Learn how Philips and Qiagen are using mRNA technology in OncoSignal tests to quantify functional activity of disease-relevant signal transduction pathways in any cell and tissue type. This webinar will explore applications for both preclinical disease modeling and clinical measurement of response to targeted therapies and immunotherapies. Register Now. |
Moderna, planning big COVID-19 capacity upgrades, pledges 500M doses to COVAX CVS assisting employers with on-site vaccine clinics through Return Ready platform How new 'lung-on-a-chip' models from Harvard are advancing COVID-19 drug discovery Glass half-full? Embattled AstraZeneca CEO Soriot defends COVID-19 vaccine With supply timelines more certain, Novavax closes in on a COVID-19 vaccine deal with Europe: report UPDATED Coronavirus tracker: Democratic Representatives urge payer CEOs to maintain COVID-19 care waivers COVID-19 tracker: Pfizer vaccine under review for adolescents in Europe; Novavax nears EU supply deal Private equity firm buys PTS to seize on COVID-19-fueled transformation of nanoparticle delivery Featured Story | By Fraiser Kansteiner Moderna recently unveiled a far-reaching manufacturing investment that could lift COVID-19 vaccine output to 3 billion doses in 2022. Now, it's pledging 500 million of those shots to COVAX, the equitable vaccine distribution scheme spearheaded by Gavi, CEPI and WHO. read more |
| |
|---|
|
Top Stories By Paige Minemyer CVS Health is now assisting employers with on-site COVID-19 vaccination clinics through its Return Ready platform. read more By Arlene Weintraub Pitting COVID-19 drug candidates against the virus in cell cultures doesn’t accurately predict how effective they’ll be in the human respiratory tract. Now more accurate models of the human lung airway are uncovering new treatment candidates. They include the antimalarial drug amodiaquine, which reduced viral load in animal models of the virus by 70%. read more By Beth Snyder Bulik As the weeks turn to months on AstraZeneca’s COVID-19 vaccine filing in the U.S., the big question is when? Its answer remains the same—soon. But with so many other shots available, why bother? read more By Kevin Dunleavy Novavax has told the European Union that it will be ready to send COVID-19 vaccine shipments to Europe before the end of the year. That could help the biotech strike a supply agreement for hundreds of millions of doses. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The European Medicines Agency said it's started an "accelerated assessment" of the Pfizer-BioNTech COVID-19 vaccine for people aged 12 to 15. Novavax is said to be nearing a finalized supply deal with the European Union for up to 200 million doses of the protein-based vaccine. And more headlines. read more By Nick Paul Taylor A private equity group has bought Polypeptide Therapeutic Solutions for its nanoparticle drug delivery technologies. Arcline Investment Management struck the deal in the belief the success of mRNA COVID-19 vaccines has permanently accelerated the rise of nanoparticle delivery. read more |
|
